The Healing Power of Botanical Therapeutics®

 
09-06-2012

Kamasutra™ Exotic Vodka With Herborium Natural Herbs: Distribution Update First order doubled

Press Release: Herborium Group, Inc. – Thu, Sep 6, 2012 7:00 AM EDT

FORT LEE, N.J., Sept. 6, 2012 /PRNewswire/ -- Herborium Group, Inc., (HBRM) www.herborium.com, a Botanical Therapeutics® Company is excited to announce that the first order for Kamasutra™ Exotic Vodka with herbal formula provided by Herborium, a pioneering specialty drink now available for the first time in the US, has been more that doubled from 1000 to 2300 cases. The full container with the product has been shipped on Monday September 3rd, from Germany and is expected to arrive in the USA before the end of September.

"Extraordinary interest in this unique novelty product, Kamasutra™ Exotic Vodka, is very exciting," commented Dr. Agnes P. Olszewski, CEO of Herborium. "The fact that the first order has been more than doubled reflects both industry recognition of the product growth potential, and consumers excitement that will help the product fly off the shelves," Added Olszewski. Kamasutra™ Exotic Vodka is the first-ever alcoholic beverage creation developed and endorsed by herbaceutical science and will appeal to a wider segment of experimental, progressive adult beverage drinkers.

The Promotion Campaign for Kamasutra™ Exotic Vodka also includes a co-promotion of Herborium's proprietary Women and Men Sexual Health formulas: Lasting Pleasure® and Lasting Power®. "We will be updating our investors soon about the different aspects of the marketing strategy for Kamasutra™ Exotic Vodka and Herborium sexual health Botanical Therapeutics® and are most optimistic about a significant impact of those products on the growth of the company," Concluded Dr. Olszewski.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sells its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com One of our most important responsibilities is to communicate with shareholders in an open and direct manner.

Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.


Investorsrelations@herborium.com: Investorsrelations@herborium.com

 

 

Information provided on Herborium.com about medical conditions, symptoms, and related products is not intended to be a substitute for professional medical advice. Visitors to this site should not use this information to diagnose or treat a health problem, symptom, concern or disease without consulting with their individual qualified healthcare provider. Statements contained on this website have not been evaluated by the FDA. Herborium products are not intended to diagnose, heal, cure or prevent disease.